Downregulation of ZNF395 Drives Progression of Pancreatic Ductal Adenocarcinoma through Enhancement of Growth Potential.


Journal

Pathobiology : journal of immunopathology, molecular and cellular biology
ISSN: 1423-0291
Titre abrégé: Pathobiology
Pays: Switzerland
ID NLM: 9007504

Informations de publication

Date de publication:
2021
Historique:
received: 09 11 2020
accepted: 19 01 2021
pubmed: 2 4 2021
medline: 8 1 2022
entrez: 1 4 2021
Statut: ppublish

Résumé

Progression of pancreatic intraepithelial neoplasia (PanIN) to invasive carcinoma is a critical factor impacting the prognosis of patients with pancreatic tumors. However, the molecular mechanisms involved are not fully understood. We have reported that the process frequently involves loss of chromosome 8p, causing downregulation of DUSP4, thus conferring invasive ability on cancer cells. Here, we focus on ZNF395, whose expression was also found to be decreased by 8p loss and was predicted to be a growth suppressor gene. Pancreatic cancer cell lines inducibly expressing ZNF395 were established to assess the functional significance of ZNF395 in pancreatic carcinogenesis. Immunohistochemistry was also performed to analyze the expression levels of ZNF395 in pancreatic cancer tissues. Induction of ZNF395 in pancreatic cancer cells resulted in marked activation of JNK and suppression of their proliferation through a delay in cell cycle progression. Immunohistochemistry revealed that ZNF395 was expressed ubiquitously in both normal pancreatic ducts and PanINs but was significantly reduced in invasive cancers, especially those showing poor differentiation. ZNF395 acts as a novel tumor suppressor gene. Its downregulation caused by 8p loss in intraepithelial cells accelerates their proliferation through dysregulation of the cell cycle, leading to progression to invasive cancer.

Sections du résumé

BACKGROUND BACKGROUND
Progression of pancreatic intraepithelial neoplasia (PanIN) to invasive carcinoma is a critical factor impacting the prognosis of patients with pancreatic tumors. However, the molecular mechanisms involved are not fully understood. We have reported that the process frequently involves loss of chromosome 8p, causing downregulation of DUSP4, thus conferring invasive ability on cancer cells. Here, we focus on ZNF395, whose expression was also found to be decreased by 8p loss and was predicted to be a growth suppressor gene.
METHODS METHODS
Pancreatic cancer cell lines inducibly expressing ZNF395 were established to assess the functional significance of ZNF395 in pancreatic carcinogenesis. Immunohistochemistry was also performed to analyze the expression levels of ZNF395 in pancreatic cancer tissues.
RESULTS RESULTS
Induction of ZNF395 in pancreatic cancer cells resulted in marked activation of JNK and suppression of their proliferation through a delay in cell cycle progression. Immunohistochemistry revealed that ZNF395 was expressed ubiquitously in both normal pancreatic ducts and PanINs but was significantly reduced in invasive cancers, especially those showing poor differentiation.
CONCLUSION CONCLUSIONS
ZNF395 acts as a novel tumor suppressor gene. Its downregulation caused by 8p loss in intraepithelial cells accelerates their proliferation through dysregulation of the cell cycle, leading to progression to invasive cancer.

Identifiants

pubmed: 33794543
pii: 000514593
doi: 10.1159/000514593
doi:

Substances chimiques

DNA-Binding Proteins 0
Transcription Factors 0
ZNF395 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

374-382

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Shusaku Kurogi (S)

Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.

Naoki Hijiya (N)

Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.

Shinya Hidano (S)

Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan.

Seiya Sato (S)

Shinbeppu Hospital, Beppu, Japan.

Tomohisa Uchida (T)

Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.

Yoshiyuki Tsukamoto (Y)

Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.

Chisato Nakada (C)

Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.

Kazuhiro Yada (K)

Department of Gastroenterological and Pediatric Surgery, Faculty of Medicine, Oita University, Yufu, Japan.

Teijiro Hirashita (T)

Department of Gastroenterological and Pediatric Surgery, Faculty of Medicine, Oita University, Yufu, Japan.

Masafumi Inomata (M)

Department of Gastroenterological and Pediatric Surgery, Faculty of Medicine, Oita University, Yufu, Japan.

Kazunari Murakami (K)

Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan.

Naohiko Takahashi (N)

Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Yufu, Japan.

Takashi Kobayashi (T)

Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan.

Masatsugu Moriyama (M)

Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH